New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
12:16 EDTMRKMerck plans to initiate Phase 3 clinical development program in 2H14
Merck presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the company’s investigational next-generation, non-nucleoside reverse transcriptase inhibitor. Interim data demonstrating potent antiretroviral activity for four doses of once-daily, oral doravirine in combination with tenofovir/emtricitabine in treatment-naïve, HIV-1 infected adults after 24 weeks of treatment were presented during a late-breaker oral session. Based on these findings, Merck plans to initiate a Phase 3 clinical trial program for doravirine in combination with ARV therapy in the second half of 2014.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
12:13 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
09:44 EDTMRKMerck CEO says has not been urged for big consolidation deal, CNBC says
Subscribe for More Information
08:32 EDTMRKMerck says not interested in deal solely, primarily for inversion
Subscribe for More Information
07:19 EDTMRKCBI to hold a conference
Subscribe for More Information
06:59 EDTMRKMerck sees FY14 revenue $42.4B-$43.2B, consensus $42.56B
Subscribe for More Information
06:58 EDTMRKMerck reports Q2 Januvia sales $1.58B, Q2 Zetia sales $1.13B
Reports Q2 Remicade sales $607M; Q2 Isentress sales $453M; Q2 Gardasili sales $409M; Q2 Proquad sales $326M; Q2 Singulair sales $284M; Q2 Nanosex sales $258M.
06:57 EDTMRKMerck sees FY14 non-GAAP EPS $3.43-$3.53, consensus $3.48
Subscribe for More Information
06:57 EDTMRKMerck reports Q2 non-GAAP EPS 85c, consensus 81c
Subscribe for More Information
July 28, 2014
15:47 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:03 EDTMRKEarnings Preview: Merck's pharmaceutical sales dependent on newer drugs
Subscribe for More Information
10:36 EDTMRKMerck August weekly volatility elevated into Q2 and outlook
Merck August weekly call option implied volatility is at 26, August is at 16, September is at 15, January is at 16; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q2 result on July 29.
July 24, 2014
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
July 21, 2014
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use